Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its Phase Ib/II study of ...

Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery ...

Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...

A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, ...

DUBLIN--(BUSINESS WIRE)--The "Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030" report has been added to ResearchAndMarkets.com's offering. Biologics represent ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients with osteoporosis preferred 6-month ...

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

Repeated insulin shots at the same site can seed amyloid; consider this diagnosis if absorption seems erratic or glucose control worsens with a persistent lump.

If you have certain types of arthritis or if you’re having a certain transplant, your doctor might suggest Orencia (abatacept) as a treatment option for you. Orencia is a prescription medication ...